Windward Bio
Drug Discovery
$365Mtotal raised · 2 rounds on record
$165Mlatest round · Venture round · May 2026 · 6 mo ago
3backers · Omega Funds, OrbiMed
50+team · employees, estimated range
Overview
Windward Bio is a clinical-stage, drug development company committed to improving outcomes for people living with serious immunological diseases.
Funding and backers
Total raised
$365M
2 rounds on record
Latest round
$165M
Venture round · May 2026 · 6 mo ago
Team
51-200
employees, estimated range
Backers
3
Omega Funds, OrbiMed
The money's age
Fresh money
6 months since the last round · not hiring
Momentum
35/100
in the news, fresh money
Last sign of life
1 mo ago
a posting or a news item
The story so fareach stage dated by its source: the company's releases, the press, registers, filings
May 5
Raised a round Venture round $165M · Startupticker.ch
Jan 13, 2025
Raised a round Series A $200M · led by OrbiMed · Pulse 2.0
Funding rounds
| Round | Date | Amount | Investors | Source |
|---|---|---|---|---|
| Venture round | May 2026 | $165M | — | Startupticker.ch |
| Series A | Jan 2025 | $200M | OrbiMed lead, Novo Holdings lead, Blue Owl Healthcare Opportu lead | Pulse 2.0 |
Backed byfrom the funds' portfolios and accelerator catalogs
Investors in similar startupsfunds that back the companies most like this one
backs Theora, AbInitio Bio
backs Babylon
backs DVLP Medicines
backs Babylon
backs Babylon
backs Babylon
Similar startupsby what they do, their industry and backers
Soricimed Biopharma is a clinical stage drug development company dedicated to novel trageted treatments for cancer.
Abinitio bio is the AI-native operating platform for drug development and manufacturing.
Psylink is a biotechnology company offering a novel solution to psychedelic drug development.
We are BioPhy, a healthcare fintech company committed to enhancing outcomes for patients and creating value for investors using our…
Babylon is a drug development company pursuing a transformational treatment for Alzheimer’s. Meet our team and explore how we discover…
Weatherden is a global drug development consultancy helping biotech and pharma realize the full potential of their science and investment.
Connections
List
Graph
Found in company registers, site code, DNS and hiring. Each connection shows how sure we are and the evidence, with its source and date.
Shared investors
SR OneVia a fund
Omega FundsVia a fund
OrbiMedVia a fund
196 portfolio companies: Cookiedatabase.org, ZYLOX-TONBRIDGE MEDICAL TECHNOLOGY CO., LTD., Z-Alpha Therapeutics and 193 more
Click a company to open it. Dashed lines are likely connections. The second step of the network is part of the Pro plan.
Owner
Same company
Same group
Likely
News
Kelun-Biotech's Partner Windward Bio Announces Positive Phase 2 Results of SKB378/WIN378 in Asthma, and Initiates Phase 3 Study
Read more
Report
Windward Bio Announces Positive Phase 2 Results Of WIN378 In Asthma Demonstrating Significant Improvements In Lung Function And Airway Inflammation With Twice-Yearly Dosing, And Initiates Phase 3
Read more
Report
Windward Bio announces positive Phase 2 results of WIN378 in asthma demonstrating significant improvements in lung function and airway inflammation with twice-yearly dosing, and initiates Phase 3
The POLARIS-1 study enrolled 147 patients with uncontrolled, moderate-to-severe asthma, and the interim analysis was conducted on the first 98 patients....
Read more
Report
Kelun-Biotech Partner Windward Bio Announces First Patients Dosed in Phase 2 SIRIUS COPD Study of SKB378/WIN378
Read more
Report
- Company Announcement - FT.com
The latest company information, including net asset values, performance, holding & sectors weighting, changes in voting rights, and directors and dealings.
Read more
Report
Windward Bio Doses First Patients in Phase 2 SIRIUS COPD Study of Ultra Long-Acting Anti-TSLP Antibody WIN378
COPD study initiation expands WIN378 development into a second major respiratory diseaseWIN378 is currently being evaluated in the Phase 2/3 POLARIS asthma...
Read more
Report
Windward Bio Announces $165 Million Crossover Financing To Advance Long-Acting Immunology Pipeline
Windward Bio, a private, clinical-stage biotechnology company based in Basel, Switzerland, has announced an upsized $165 million crossover financing led by OrbiMed, with participation from RA Capital Management, Janus Henderson Investors, Sanofi Ventures,
Read more
Report
Windward Bio Announces $165M Crossover Financing to Advance Pipeline of Long-Acting Immunology Therapies With Best-in-Disease Potential
Led by OrbiMed, with participation from RA Capital Management, Janus Henderson Investors, Sanofi Ventures, Harbour BioMed, and existing investors Proceeds will advance lead candidate WIN378 into Phase 3 and WIN027 into respiratory and dermatology studies
Read more
Report
Windward Bio Announces $165M Crossover Financing to Advance Pipeline of Long-Acting Immunology Therapies With Best-in-Disease Potential
Led by OrbiMed, with participation from RA Capital Management, Janus Henderson Investors, Sanofi Ventures, Harbour BioMed, and existing investors Proceeds...
Read more
Report
Windward Bio Expands Immunology Pipeline With WIN027, a Long-Acting, Clinical-Stage Bispecific Targeting TSLP and IL-13
Windward Bio and Qyuns Therapeutics announce licensing agreement for WIN027, a highly potent, long-acting bispecific antibody with best-in-disease potential in respiratory and dermatologyWIN027 blocks 2 well-validated and synergistic drivers of inflammati
Read more
Report
Show more news